Enlivex Bets on RAIN Tokens, Potential Ninefold Share Increase Tests Its Identity as a Biotech Company

A biotech company that still needs to continue investing in clinical development is preparing to tie its balance sheet more closely to a crypto token. Israel-based Enlivex has signed a $400 million private placement agreement with the RAIN Foundation and secured the right to require it to subscribe for up to another $400 million of shares over the next three years. If approved by shareholders and fully executed, the transaction could completely reshape the company’s equity structure.

The subscription price for the initial shares varies by payment method: $5 per share if paid in U.S. dollars or stablecoins, and $6 per share if paid in RAIN tokens. The RAIN Foundation currently intends to pay in RAIN, but may still change its choice before closing. Based on the current selection, approximately 66.67 million shares could be issued in the first tranche. If both tranches are instead fully executed at the $5 price, as many as 160 million new shares could be issued, equivalent to 951% of Enlivex’s approximately 16.83 million shares outstanding after its reverse split. This is the increase in the number of shares, not a 951% decline in existing shareholders’ ownership percentages; the two should not be confused.

Another layer of risk in the transaction is that the buyer, the payment asset, and the intended use of proceeds all revolve around the same RAIN ecosystem. The RAIN Foundation both manages the token ecosystem and is an existing Enlivex shareholder. If the transaction is settled in tokens, Enlivex would receive more RAIN rather than cash that could directly fund trial expenses. If payment is made in U.S. dollars or stablecoins, the company’s filings indicate that most of the net proceeds are still intended for the RAIN strategy, with the remainder used for debt repayment and transaction expenses.

Enlivex has not entirely abandoned its biotech business. The company said it will continue advancing the cell immunotherapy Allocetra, currently focusing on age-related knee osteoarthritis. However, the transaction terms do not earmark a specific amount for clinical development. The company’s previous filings have also acknowledged that its clinical operations do not yet generate revenue and that future research and development will require additional funding. Whether this nominally large private placement can actually extend the runway for drug development therefore depends on whether the tokens can be converted into usable cash.

Although RAIN is listed on several cryptocurrency exchanges, its book valuation does not equal its realizable value. Enlivex would hold a large quantity of tokens, and if market trading depth is insufficient, large-scale sales could depress the price. Token prices, custody security, regulatory rules, and related-party concentration could also make the company’s value more susceptible to factors beyond clinical data.

From a corporate governance perspective, shareholders face more than a single large-scale capital increase. The transaction also includes pre-funded warrants and allows Enlivex to decide on its own whether to initiate the second $400 million subscription tranche within 36 months. The actual degree of dilution will depend on the payment method, whether the second-tranche right is exercised, and the instruments ultimately issued. The maximum scenario cannot be treated as though it has already occurred.

The transaction remains subject to shareholder approval as required under Israeli law and Nasdaq rules. The central question in the vote is whether the capital of a clinical-stage biotech company should primarily support verifiable drug-development milestones or be concentrated in a highly volatile digital asset whose convertibility has yet to be tested by the market. Until the company provides clearer research and development budgets and token-liquidity data, the allocation of resources between these two paths remains opaque.